2. Signaling Pathways
  3. Antibody-drug Conjugate/ADC Related
  4. Drug-Linker Conjugates for ADC

Drug-Linker Conjugates for ADC

ADC-Related Custom Services

Drug-Linker Conjugates for ADC

Related Products

PDF 0.45 MB

Drug-Linker Conjugates for Antibody Drug Conjugates (ADCs) comprise of an active cytotoxic drug and an appropriate linker. After linked to a monoclonal antibody, those conjugates can be used for making ADCs, which are targeted agents for cancer cells with high selectivity and cytotoxicity.

The drug units in drug-linker conjugates are cytotoxic agents (i.e. ADC cytotoxins or payloads) with antitumor activity and can be classified in DNA damaging agents and tubulin inhibitors. The most commonly used DNA damaging agents in ADCs are Duocarmycins, Pyrrolobenzodiazepines, Camptothecins and Daunorubicins/Doxorubicins, while the popular tubulin inhibitors are Auristatins and Maytansinoids. Besides, there are also many traditional cytotoxic agents can be used in ADCs.

ADC linkers currently undergoing clinical evaluation are mostly classified into two categories: cleavable and noncleavable. Cleavable linkers rely on processes inside the cell to liberate the toxin, and noncleavable linkers require proteolytic degradation of the antibody portion of the ADC for release of the cytotoxic molecule.

Drug-Linker Conjugates for ADC Isoform Specific Products:

Drug-Linker Conjugates for ADC Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-204602
    Fmoc-Val-Cit-PAB-MMAF-OtBu
    Fmoc-Val-Cit-PAB-MMAF-OtBu is a conjugate of MMAF and ADC linker, which can be coupled with the corresponding antibody to form an ADC molecule to exert anti-tumor activity.
    Fmoc-Val-Cit-PAB-MMAF-OtBu
  • HY-186048
    MC-VC-PAB-Daptomycin
    MC-VC-PAB-Daptomycin (Compound 54) is the linker-payload of an antibody-drug conjugate (ADC). β-Glucuronide-dPBD-PEG6-NH2 is composed of Daptomycin (HY-13631), a lipopeptide antibiotic, and the linker.
    MC-VC-PAB-Daptomycin
  • HY-148346
    STING agonist-20-Ala-amide-PEG2-C2-NH2
    STING agonist-20-Ala-amide-PEG2-C2-NH2 is an active scaffold comprising a stimulator of interferon genes (STING). STING agonist-20-Ala-amide-PEG2-C2-NH2 can be used to synthesize immune-stimulating antibody conjugate (ISAC). STING agonist-20-Ala-amide-PEG2-C2-NH2 can be used for the research of cancer.
    STING agonist-20-Ala-amide-PEG2-C2-NH2
  • HY-173243
    Val-Ala-PAB-SN38
    Val-Ala-PAB-SN38 is a drug-linker conjugate for ADC, composed of ADC linker Val-Ala-PAB (HY-125933) and SN38 (HY-13704), which is the active metabolite of the Topoisomerase I inhibitor Irinotecan (HY-16562).
    Val-Ala-PAB-SN38
  • HY-155870
    DL-01
    DL-01 is a drug-linker conjugates for ADC that can be used for the synthesis of ADCs.
    DL-01
  • HY-177307A
    Mal-Val-Lys-PAB-MMAE TFA
    		98.41%
    Mal-Val-Lys-PAB-MMAE TFA is a drug-linker conjugate for ADC. Mal-Val-Lys-PAB-MMAE TFA consists of a Tubulin inhibitor (MMAE) (HY-15162) and a linker (Mal-Val-Lys-PAB). Mal-Val-Lys-PAB-MMAE TFA can be used for synthesis of ADCs.
    Mal-Val-Lys-PAB-MMAE TFA
  • HY-126684
    Mal-PEG4-VC-PAB-DMEA-Seco-Duocarmycin SA
    Mal-PEG4-VC-PAB-DMEA-Seco-Duocarmycin SA is a agent-linker conjugate for ADC by using the antitumor antibiotic, Duocarmycin SA, linked via Mal-PEG4-VC-PAB-DMEA-Seco.
    Mal-PEG4-VC-PAB-DMEA-Seco-Duocarmycin SA
  • HY-178219
    Bis-sulfone-(PEG24)-Glu-Val-Cit-PAB-MMAE
    Bis-sulfone-(PEG24)-Glu-Val-Cit-PAB-MMAE is a drug-linker conjugate for ADC. Bis-sulfone-(PEG24)-Glu-Val-Cit-PAB-MMAE contains a linker and bioactive small molecule toxins MMAE (HY-15162). Bis-sulfone-(PEG24)-Glu-Val-Cit-PAB-MMAE can conjugate with NN2101 (HY-P991293) (anti c-Kit) for synthesizing NN3201. NN3201 rapidly internalizes and inhibits SCF-driven signaling, thereby delivering its payload to induce cell cycle arrest and apoptosis. NN3201 exhibits significant c-Kit-dependent anti-tumor efficacies in various tumor models, such as small cell lung cancer (SCLC) and gastrointestinal stromal tumor (GIST).
    Bis-sulfone-(PEG24)-Glu-Val-Cit-PAB-MMAE
  • HY-P11779
    Ac-RKAA-PABC-MMAE
    Ac-RKAA-PABC-MMAE is a Drug-Linker Conjugates for ADC. Ac-RKAA-PABC-MMAE consists of the ADC Cytotoxin MMAE (HY-15162) and a linker. Ac-RKAA-PABC-MMAE can be used for synthesis of ADCs.
    Ac-RKAA-PABC-MMAE
  • HY-171931
    Aminocaproyl-Val-Cit-PABC-Exatecan
    Aminocaproyl-Val-Cit-PABC-Exatecan is a drug-linker conjugate for ADC, consiting of a cleavable linker (Aminocaproyl-Val-Cit-PABC) and Exatecan (HY-13631) (topoisomerase I inhibitor). Aminocaproyl-Val-Cit-PABC-Exatecan can be used for ADC molecues synthesis.
    Aminocaproyl-Val-Cit-PABC-Exatecan
  • HY-157284
    Cys-mc-MMAE
    		99.85%
    Cys-mc-MMAE is a Drug-Linker Conjugates for ADC, and consists of Monomethyl auristatin E (HY-15162) and a linker. Cys-mc-MMAE can be used for synthesis of ADCs.
    Cys-mc-MMAE
  • HY-186031
    LD-114
    LD-114 is an agent-linker conjugate that can be used to make an antibody agent conjugate (ADC).
    LD-114
  • HY-131158
    DBCO-PEG3-Glu-VC-PABC-MMAF
    DBCO-PEG3-Glu-VC-PABC-MMAF (compound s19b) is a drug-linker conjugate for ADC by using the tubulin inhibitor, MMAF (HY-15579), linked via cathepsin cleavable DBCO-PEG3-Glu-VC-PABC. DBCO-PEG3-Glu-VC-PABC-MMAF can be used in the synthesis of antibody-drug conjugates (ADCs).
    DBCO-PEG3-Glu-VC-PABC-MMAF
  • HY-176415S
    Cys-MC-GGFG-Dxd-d5
    Cys-MC-GGFG-Dxd-d5 is the deuterium labeled Cys-MC-GGFG-Dxd (HY-176415). Cys-MC-GGFG-Dxd is a conjugate of Cys and Deruxtecan (HY-13631E). Cys-MC-GGFG-Dxd is a linker-toxin building block in antibody-drug conjugates (ADCs) used to link antibody Cys residues to cytotoxic drugs. Cys-MC-GGFG-Dxd can be used in cancer research.
    Cys-MC-GGFG-Dxd-d<sub>5</sub>
  • HY-156691A
    TLR7/8 agonist 4 hydroxy-PEG6-acid hydrochloride
    TLR7/8 agonist 4 hydroxy-PEG6-acid hydrochloride is a drug-linker conjugates for ADC>. TLR7/8 agonist 4 hydroxy-PEG6-acid hydrochloride is the hydrochloride form of TLR7/8 agonist 4 hydroxy-PEG6-acid. TLR7/8 agonist 4 hydroxy-PEG6-acid consists of TLR7/8 agonist 4 (HY-139017) and a non-cleavable linker Hydroxy-PEG6-acid (HY-133050), and can be used for synthesis of ADCs.
    TLR7/8 agonist 4 hydroxy-PEG6-acid hydrochloride
  • HY-138269
    Barzuxetan
    Barzuxetan can be used for cancer diseases research.
    Barzuxetan
  • HY-15575R
    VcMMAE (Standard)
    VcMMAE (Standard) is the analytical standard of VcMMAE. This product is intended for research and analytical applications.
    VcMMAE (Standard)
  • HY-160899A
    Thailanstatin A cyclohexane diamine formic
    Thailanstatin A cyclohexane diamine formic is an analog of Spliceostatin (HY-16466). Thailanstatin A cyclohexane diamine formic inhibits proliferations of cells N87 (IC50 is 0.33 μM), BT474 (IC50 is 0.34 μM), MDA-MB-361-DYT2 (IC50 is 0.88 μM) and MDA-MB-468 (IC50 is 0.27 μM). Thailanstatin A cyclohexane diamine formic is used as a drug-linker conjugate for ADC molecule.
    Thailanstatin A cyclohexane diamine formic
  • HY-157465A
    MA-PEG4-VC-PAB-DMEA-duocarmycin DM TFA
    		99.05%
    MA-PEG4-VC-PAB-DMEA-duocarmycin DM TFA is a drug-linker conjugate for ADC by using the DNA minor-groove alkylator Duocarmycin DM (HY-130978), linked via MA-PEG4-vc-PAB-DMEA (HY-126668).
    MA-PEG4-VC-PAB-DMEA-duocarmycin DM TFA
  • HY-176415S1
    Cys-MC-GGFG-Dxd-d5 TFA
    Cys-MC-GGFG-Dxd-d5 TFA (Cys-MC-GGFG-Dxd-d5 TFA) is the deuterium labeled Cys-MC-GGFG-Dxd (HY-176415). Cys-MC-GGFG-Dxd-d5 TFA is a conjugate of Cys and Deruxtecan (HY-13631E). Cys-MC-GGFG-Dxd-d5 TFA is a linker-toxin building block in antibody-drug conjugates (ADCs) used to link antibody Cys residues to cytotoxic drugs. Cys-MC-GGFG-Dxd-d5 TFA can be used in cancer research.
    Cys-MC-GGFG-Dxd-d5 TFA
Drug-Linker Conjugates for ADC Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.